Curadel Pharma

CPI-003 is Curadel’s lead zwitterionic targeted alpha therapy for metastatic cancer, designed for rapid tumor binding and renal clearance.

Curadel uses zwitterionicity to reduce non-specific binding and background signals in optical imaging agents for real-time surgical guidance.

Curadel Pharma develops scientific advancements to improve cancer detection, diagnosis, and treatment.

For surgeons resecting solid tumors or navigating intricate anatomical structures, precise visual clarity isn't just an advantage. It is the bridge to better patient outcomes.

Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and imaging drugs, announced the initiation of a pivotal study evaluating its investigational imaging-guided drug ZW800-1 (nizaracianine triflutate) to highlight the ureter during abdominopelvic surgery.

Curadel Pharma has begun Phase 3 trials for ZW800-1 (nizaracianine triflutate), a drug to highlight the ureter during abdominopelvic surgery.

Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and imaging drugs, announced completion of a Series A2 funding round, securing $10.5M to advance early stage development for its lead programs.

US and EU regulatory designations provide critical development resources to advance novel tumor detection technology

Dr. Frangioni pioneered zwitterionicity for cancer imaging and treatment, previously serving as Professor of Medicine and Radiology at Harvard Medical School.

Dr. O’Riordan has regulatory experience in microbiology R&D and scientific writing, with roles at X4 Pharmaceuticals, Finch Therapeutics Group, and Parexel Consulting.

Current targeted alpha therapies (TATs) may cause tissue damage and resistance, limiting long-term survival for metastatic cancer patients.

The company says current and emerging TATs can shrink tumors but may not deliver long-term survival in metastatic cancer, citing tissue damage, poor tolerability, clonal evolution and delayed redosing as risks for tumor regrowth and resistance.

Curadel applies zwitterionic technology to enhance targeted alpha therapy outcomes.

The company uses proprietary zwitterionic technology for targeted alpha therapy (TAT).

CURADEL’s privacy policy explains what personal information it collects from customers and visitors to its websites, how it uses the information, and what choices are available before people provide it.

The Curadel Environmental Monitoring System (EMS) uses SMS text messaging to deliver business-critical notifications related to environmental monitoring, operational events, employee safety, and regulatory compliance.

CPI-008 secures orphan drug designation from the FDA and EMA, improving surgical imaging for pancreatic cancer. The drug aims to enhance precision during complex surgeries, potentially addressing diagnostic challenges in the disease. Development focuses on supporting better treatment outcomes for patients with limited therapeutic options.

Jan 2026targetedonc.comNews article

Curadel Pharma receives Orphan Drug Designation from the FDA and EMA for **CPI-008**, an integrin-targeted imaging agent designed to improve pancreatic cancer margin detection during surgery. The drug leverages zwitterionic chemistry to enhance precision in identifying tumor boundaries. This designation accelerates development for rare diseases, including pancreatic cancer, by offering regulatory incentives.

Jan 2026Curadel PharmaNews article

TRACER enrolls the first patient in the **TRIPHASE** clinical trial (NCT06101745) at a TRACER-managed site. The patient, treated at **Isala Hospital** in Zwolle, receives **ZW800-1**, a near-infrared fluorophore developed by **Curadel Pharma**, during abdominopelvic surgery. This marks a key milestone in the trial’s progress.

Sep 2025TRACERNews article

Curadel Pharma is proposing a 43,000-square-foot cancer treatment facility in Estero, Florida, designed by Naples oncologist Dr. John Frangioni. The center will specialize in targeted alpha therapy, attracting patients globally. The Mediterranean Revival-style building will house advanced oncology services under Curadel Pharma’s initiative.

Aug 2025Gulfshore BusinessNews article